top of page
BioSyngen
BioSyngen
linkedin
linkedin

Supported projects

Biosyngen

Specializing in the development of innovative cell therapies - chimeric antigen receptor T cells (CAR-T), T cell receptor T cells (TCR-T) and tumor-infiltrating lymphocytes (TIL) - for the treatment of cancer.

PSCC's entrance

Décembre 2025

Localization

Singapore

Modality

Cell & Gene therapy

Development status

Biotech - Phase 2

Lauréat (s)

bottom of page